Pathological Complete Response with Neoadjuvant Trastuzumab Combined with Chemotherapy in HER2 Positive Breast Cancer: A Single Institution Retrospective Analysis from Vietnam.
Huyen Thi PhungHoa Thi NguyenTung Van NguyenTai Van NguyenLan Anh Thi DinhVan Chu NguyenPublished in: Breast cancer (Dove Medical Press) (2020)
Neoadjuvant treatment with trastuzumab and chemotherapy combined in patients with HER2 positive breast cancer yielded a pathological complete response rate of 64.1%.